1Furuhashi M, Ura N, Hasegawa K, et al. Sonoclot coagulation analysis: new bedside monitoring for determination of the appropriate heparin dose during haemodialysis. Nephrol Dial Transplant, 2002, 17: 1457-1462.
2Molino D, De Santo NG, Marotta R, et al. Plasma levels of plasminogen activator inhibitor type 1, factor Ⅷ, protbrombin activation fragment 1 +2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol, 2004, 24: 495-501.
3Sirolli V, Strizzi L, Di Stante S, et al. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Haemost, 2001, 86: 834- 839.
4Nutescu EA, Shapiro NL, Chevalier A, et al. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med, 2005, 72: S2-S6.
6Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int, 2007, 11: 178-189.
7Fareed J, Ma Q. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosisl Semin Thromb Hemost, 2004, 30: 89-104.
8Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother, 2005, 39: 231-236.
9Sagedal S, Hartmann A, Sundstrφm K, et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant, 2001, 16: 987-993.
